- You are here »
- Search »
- Lyme disease »
Search Results for: Lyme disease
Post-treatment Lyme Disease Syndrome and Language Fluency Deficits
Marianne Gorlyn, et al., published “Language Fluency Deficits in Post-treatment Lyme Disease Syndrome” in Archives of Clinical Neuropsychology on December 12, 2022. The goal of the study was to ascertain whether language fluency deficits could be explained by poor performance in these other neurocognitive areas as well as to determine whether they are secondary to poor memory and slowing rather than an independent deficit.
Breaking News: Borrelia garinii, Agent of Lyme Disease, Confirmed in US
Natalie Rudenko, et al., published in Emerging Infectious Diseases Jan. 2023 “Confirmation of Borrelia garinii, United States.” Currently, Borrelia burgdorferi ss, B. garinii, and B. afzelii –members of the Borrelia burgdorferi sl complex– cause most Lyme disease throughout the world.
Lyme Disease Vaccine Candidate VLA15 Shows Antibodies 6 Months Post Completion
ContagionLive published the article “Lyme Disease Vaccine Shows Antibodies 6 Months after Completion” by Senior Editor, John Parkinson, on December 1, 2022. The article provides details of the most recent investigational outcomes for Pfizer and Valneva’s Lyme disease vaccine candidate, VLA15.
Pat Smith Presents Milestones in 47 Year History of Lyme Disease & Her Story
PA Lyme Resources Presents Lyme Impact Series – LDA President, Pat Smith on Lyme Disease: 47 years – Past, Present & Moving Forward, May 17th, 2022 TOPICS COVERED IN VIDEO: […]
Researchers Discover Gene Set That Predicts Post-Treatment Lyme Disease
Daniel J.B. Clarke, et al, published “Gene set predictor for post-treatment Lyme disease” in Cell Reports Medicine on November 15, 2022. The researchers enrolled 152 study participants, each with symptoms of post-treatment Lyme disease (PTLD), to analyze their peripheral blood mononuclear cells (PBMCs) with RNA sequencing (RNA-seq). RNA-seq data from 72 individuals with acute Lyme disease and 44 uninfected controls were incorporated to examine variations in differential gene expression.
Tarsus Pharmaceuticals Announces Initiation of Phase 2a Trial of Lyme Disease Prevention Therapeutic
As reported on WDRB.com on November 9, 2022, from Tarsus Pharmaceuticals, Inc, (GLOBAl NEWSWIRE), Tarsus “is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.”
First Run Features Acquires The Quiet Epidemic a Documentary About Chronic Lyme Disease
First Run Features, an independent film distribution company, has acquired U.S. rights to The Quiet Epidemic, a documentary film about Chronic Lyme and other tick-borne diseases.
Duke University School of Law Lyme Disease Advocacy Project
LDA Guest Bloggers – Luke Mears & Madison Pinckney are second-year law students at Duke University School of Law. We formed the Lyme Disease Advocacy Project in February of 2022 after our experiences contracting and combating Lyme disease. Our hope for the project was multifaceted. We sought to provide legal research and writing for the Lyme Disease Association, Inc. (LDA) hoping to answer legal questions as they lobbied for increased resources and better treatment for Lyme disease.
Montreal Hospital Opens Clinic for Long-COVID and Lyme Disease Patients
According to a Montreal Gazette article, an announcement was made by the CIUSSS West-Central Montreal regional health authority, on October 31, 2022, that a clinic for patients with persistent COVID-19 and Lyme disease symptoms has opened at the Jewish General Hospital in Montreal, Quebec, Canada. Earlier this year, Quebec announced plans to open 15 clinics that will specialize in long COVID and Lyme disease, as well as five referral centers and 10 satellite clinics.
